Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Financial terms were not disclosed.
Alan Shaw, president and CEO of Codexis, said: “Codexis is very pleased to be partnering with Teva, providing high value technology in the extremely cost-competitive generics marketplace.
“Our proven technology reduces the cost of pharmaceutical process development and manufacturing, and provides our partners with a significant competitive advantage as they respond to increasing market demands for lower cost pharmaceuticals.”